The Generalized Anxiety Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Generalized Anxiety Disorder: An Overview
Generalized anxiety disorder (GAD) is characterized by persistent, excessive, and unrealistic worry about everyday things. This worry could be multifocal, such as finance, family, health, and the future. It is in excess, is difficult to control, and is often accompanied by many nonspecific psychological and physical symptoms. Excessive worry is the central feature of GAD.
The criteria of GAD in DSM-V include the characteristics, such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness.
Excessive worry and anxiety occur most of the time for at least 6 months with at least three of the core symptoms in adults and one sign in the case of children. GAD often occurs along with other mental health problems, which can make diagnosis and treatment more challenging. Some mental health disorders that commonly occur with GAD are phobias,
Generalized Anxiety Disorder Market Key Facts
As per DelveInsight estimates, the 12-month prevalent population of Generalized Anxiety Disorder in 7MM was found to be 16,606,900+ in 2017.
Among all the countries, the estimates show the highest population of Generalized Anxiety Disorder in the US in 2017.
Among the EU5 countries, France has the highest prevalent cases with 1,304,900+ cases in 2017, followed by the UK. On the other hand, Spain had the lowest prevalent population.
Among the Gender-specific cases, females are found to be twice as commonly affected as males in all the countries.
Generalized Anxiety Disorder Market
As per DelveInsight assessments, the Generalized Anxiety Disorder (GAD) therapeutics market size is expected to increase significantly in the 7MM during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Generalized Anxiety Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Generalized Anxiety Disorder market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Generalized Anxiety Disorder Epidemiology
The epidemiology section covers insights into the historical and current Generalized Anxiety Disorder patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Generalized Anxiety Disorder Epidemiology Subtype Segmentation –
Total 12-Month Prevalent Cases
Gender-specific Cases
Age-Specific Cases
Severity-Specific Cases
Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched in the market during the study period. The analysis covers Generalized Anxiety Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Generalized Anxiety Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
Generalized Anxiety Disorder Therapeutics Analysis
The Generalized Anxiety Disorder market is expected to increase during the forecast period owing to the launch of upcoming therapies in the 7MM.
Some of the key companies in the Generalized Anxiety Disorder Market include:
Bionomics
Sage Therapeutics
VistaGen Therapeutics
Fabre-Kramer Pharmaceuticals
Forest Laboratories/ Allergan
And others
Generalized Anxiety Disorder Therapies Covered in the report include:
BNC210
Travivo
SAGE-217
PH94B
Vilazodone
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Generalized Anxiety Disorder Competitive Intelligence Analysis
4. Generalized Anxiety Disorder Market Overview at a Glance
5. Generalized Anxiety Disorder Disease Background and Overview
6. Generalized Anxiety Disorder Patient Journey
7. Generalized Anxiety Disorder Epidemiology and Patient Population
8. Generalized Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Generalized Anxiety Disorder Unmet Needs
10. Key Endpoints of Generalized Anxiety Disorder Treatment
11. Generalized Anxiety Disorder Marketed Products
12. Generalized Anxiety Disorder Emerging Therapies
13. Generalized Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Generalized Anxiety Disorder Market Outlook (7 major markets)
16. Generalized Anxiety Disorder Access and Reimbursement Overview
17. KOL Views on the Generalized Anxiety Disorder Market.
18. Generalized Anxiety Disorder Market Drivers
19. Generalized Anxiety Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Food Allergy Market
DelveInsight’s “Food Allergy Market” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology, as well as the Food Allergy Market Trends in the 7MM. Some of the key companies in the Food Allergy Market include Aimmune Therapeutics, Novartis, DBV Technologies, InnoUp Farma, Cour Pharmaceutical Development Company, Vedanta Biosciences, Regeneron Pharmaceuticals, Genentech, Rho Federal Systems Division, Alladapt Immunotherapeutics, Camallergy, and Others.
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/dyslipidemia-market
